Clinical Genomics Market Surges in 2025 with NABL-Accredited Molecular Labs and AI-Integrated Platforms

The global clinical
genomics market is valued at approximately US$1.06 billion in 2024 and
is expected to rise to US$1.25 billion in 2025. Looking ahead, the market is
projected to reach around US$5.34 billion by 2034, expanding at a robust CAGR
of 17.54% from 2025 to 2034.

Get a free preview of the Clinical
Genomics Market report, featuring key insights and trends: https://www.towardshealthcare.com/download-sample/5754

Growing instances of genetic diseases and
cancer, advancements
in genomic technologies, including next-generation
sequencing (NGS), and rising
demand for precision medicine are driving the global clinical genomics
market. Furthermore, boosting awareness about the advantages of genomic testing
among patients and healthcare providers is accelerating the market growth. It
mainly encompasses early disease detection, better treatment selection, and enhanced
patient outcomes. Besides this, government initiatives and escalated
investments in genomic research and development are propelling the further
market expansion.

Clinical Genomics Market Highlights:

• The clinical genomics sector is pushing
the market to USD 1.06 billion in 2024.

• Long-term projections show a USD 5.34
billion valuation by 2034.

• Growth is expected at a steady CAGR of
17.54% between 2025 to 2034.

• North America led the global clinical
genomics market share in 2024.

• Asia Pacific is expected to register the
fastest growth in the projected period.

• By test type, the diagnostic testing
segment was dominant in the market in 2024.

• By test type, the genetic testing
segment is expected to grow at the fastest CAGR during the forecast period.

• By method type, the biochemical tests
segment held a major revenue share of the market in 2024.

• By method type, the molecular tests
segment is expected to be the fastest growing during 2025-2034.

• By end user, the hospitals & clinics
segment held the dominating revenue share of the global clinical genomics
market in 2024.

• By end user, the academic and research
institutes segment is expected to grow fastest in the upcoming years.

Access detailed market data, segment
analysis, and growth projections in our exclusive databook: https://www.towardshealthcare.com/download-databook/5754

Market Overview

Clinical genomics is a branch of genomics
in which information from an individual patient’s genome is used to inform
clinical decision-making. Primarily, this clinical genomics market is fueled by
the increasing cases of cancer, genetic diseases, and infectious conditions
that need advanced genomic analysis for diagnosis and prognosis, and treatment,
along with advancements in technologies, including NGS, long-read
sequencing, and CRISPR, are providing cost-effective, rapid, and
accessible solutions. As well as Integrating
AI with genomics is a major emerging trend that can boost research
activities and enhance diagnostics.

Widespread Applications in Diagnostics
and Drug Development: Major Potential

Clinical genomics has various opportunities
across the globe, including its high use to diagnose different conditions like
genetic disorders, cancer, infectious diseases, and prenatal
conditions. Along with this, in the drug
discovery and development area, it helps to determine drug targets,
estimate drug responses, and develop novel drug candidates. Clinical-based
genomics supports to analysis individual’s genome, and clinicians can choose
the highly efficacious and safe medications and therapies, which further
enhance the development
of personalized medicine.

Accelerating Expenditure on Technology
and Infrastructure: Major Limitation

In the clinical genomics market, for the
settings and maintenance of genomic facilities, major investments are needed in
specialized reagents and bioinformatics
infrastructure, which is generating limitations for smaller
institutions and healthcare facilities. Also, a shortage of skilled
professionals in areas including bioinformatics, data analysis, and
interpretation creates a barrier to market expansion.

You can place an order or ask any
questions, please feel free to contact us at sales@towardshealthcare.com

The Clinical Genomics Market: Regional
Analysis

North America dominated the market with the
biggest revenue share in 2024. The respective market is driven by the growing
incidence of chronic and inherited diseases such as cancer, cardiovascular
diseases, and genetic disorders, which increasingly demand advanced diagnostic
and treatment solutions offered by clinical genomics. Also, this region is
advancing NGS technology with cost-effective and accessible solutions, allowing
large-scale genomic studies and fueling its adoption in clinical settings for
diagnostics and research.

The most influential country in North
America is the US, which is widely adopting personalized medicine by detecting
genetic markers that indicate disease risks, supporting treatment decisions,
due to the major role of clinical genomics in these results in the development
of targeted therapies. Besides this, NIH’s funding for genomic research
is significantly contributing to the clinical genomics market growth.

Whereas, Canada is stepping towards
awareness among healthcare professionals and the public about adoption and
greater application of genomics which resulting in raised demand for genomic
services in hospitals and clinics. As well as the Canadian government is
increasingly investing in genomic research and infrastructure, such as the
Canadian Genomics Strategy, which is driving the ultimate market growth.

The Asia Pacific is Anticipated to Grow
at a Rapid CAGR During the Forecast Period

Rising different health concerns like
genetic disorders, heart diseases, diabetes, and infectious diseases such as
COVID-19 are widely demanding highly effective and safe personalized therapies
ASAP. This demand is resulting in the fastest clinical genomics market growth. As
well as ASAP is developing less expensive NGS technology for more approachable
to various laboratories and research institutions.

Mainly, China is experiencing major growth
due to the rising
adoption of biotechnologies in various aspects of health, also they are
putting efforts to develop innovative therapies for genetic disorders. Also,
the Chinese government is emphasizing boosting awareness about health concerns
and funding for R&D in biology collaborations
with different biopharmaceutical and bioinformatics companies.

Whereas India has numerous opportunities in
clinical genomics, as the number of cases is increasing. Also, India is greatly
adopting novel technologies like NGS and CRISPR to develop patient-based,
tailored medicines for genetic concerns, diabetes, and heart diseases.

Get the latest insights on life science
industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Recent Updates of ASAP Countries

Company or Country

Recent Updates

China (February 2025)

Launched an AI model, PUMCH-GENESIS, to diagnose rare diseases.

Japan’s ELECOM (February 2025)

MediBuddy partnered with Japan’s ELECOM to launch Smart Health IoT
Devices in India.

India (February 2025)

IIT Madras unveiled a public access cancer genome database to
support cancer research, drug discovery in India.

Japan (January 2025)

Taiwan’s advanced genomics and cancer precision medicine
collaborated to launch a bladder cancer screening test in Japan.

ACT Genomics (July 2024)

ACT Genomics and LSI Medience signed an MOU to form a partnership
and collaborate in the Japanese market.

The Clinical Genomics Market
Segmentation Analysis

By test type analysis

The diagnostic testing segment dominated
the market in 2024. Major impacting factor is rising cases of cancer,
cardiovascular diseases, and genetic disorders which demand for early and
precise diagnosis is critical for effective management and treatment of these
conditions, making genomic testing an essential tool and accelerating demand
for diagnostic testing.

Whereas the genetic testing segment is
expected to grow rapidly during 2025-2034. The growing development of faster
and affordable
sequencing techniques like NGS for complete genomes or specific gene
panels is fueling demand for applications of genetic testing. As well as
polymerase chain reaction (PCR) technology supports as a consistent and vital
tool for genetic testing segment growth.

By method type analysis

The biochemical tests segment was dominant
in the clinical genomics market in 2024. Applications of biochemical tests are
vital in the identification of genetic and metabolic concerns in newborns,
enabling prior intervention and management is a major driver of this segment’s
growth. Also, these tests enhance timely treatments and optimize patient
results, along with their cost-effectiveness property over some advanced
genomic techniques, making them a preferred choice for a large-scale screening
process.

On the other hand, the molecular tests
segment is predicted to register the fastest growth in the upcoming years.
Groundbreaking technologies such as PCR, NGS, and point-of-care testing have
enhanced the capabilities and uses of molecular tests by allowing more accurate
and robust testing is propelling the segment and market expansion. Molecular
tests are also playing a major role in the development of precision medicine by
detecting specific genetic markers.

By end-user analysis

The hospitals & clinics segment led the
global clinical genomics market in 2024. However, hospitals and clinics possess
the integration of genomic testing into routine care, such as hereditary cancer
screening, pharmacogenomics, rapid sequencing in neonatal intensive care units
(NICUs), and oncology
centers. Along with improved healthcare facilities and government
support is boosting the segment expansion.

The academic and research institutes
segment is anticipated to show the fastest growth during the forecast period.
Primarily, both the government and private sectors are investing increasingly
in genomic research, allowing important financial support to academic and
research institutions. Besides this, these institutions are employing genomics
services to study gene structure, function, and variations, resulting in
discoveries and advancements in healthcare.

Elevate your
healthcare strategy with Towards Healthcare. Enhance efficiency and drive
better outcomes schedule a call today: https://www.towardshealthcare.com/schedule-meeting

Top 10 Companies and Their Contributions
to the Market

Company

Latest Contribution / Offering

Illumina, Inc.

Continues to power precision medicine with its global NGS
platforms and actively supports comprehensive genomic profiling for research
and diagnostics.

Quest Diagnostics

Expands precision oncology with its Haystack MRD liquid biopsy and
Alzheimer’s blood biomarkers p‑tau217/p‑tau181 tests.

PerkinElmer, Inc.

Drives high-throughput clinical genomics via automated assay
systems used in major diagnostic laboratories worldwide.

Eurofins Scientific SE

Delivers large-scale NGS and bioinformatics services through
Eurofins Genomics to thousands of clients globally.

Rosetta Genomics Ltd.

Leads in miRNA-based diagnostics for lung and other cancers,
offering assays for clinical decision support.

NeoGenomics Inc.

Debuted the PanTracer tumor profiling suite and Paletrra spatial‑proteomics
platform at ASCO 2025 for advanced cancer diagnostics.

Invitae Corporation

Strengthens its focus on hereditary and reproductive testing under
the pending LabCorp acquisition.

Foundation Medicine, Inc.

Supports precision oncology through its comprehensive genomic
profiling assays integrated into partner workflows.

Genomic Health, Inc.

Exact Sciences continues to deliver Oncotype DX breast‑cancer
recurrence testing across diverse populations.

Natera, Inc.

Presented ASCO 2025 data highlighting pan-cancer Signatera MRD
sensitivity at 94% and specificity at 100%, and expanded soft‑tissue sarcoma
validation.

Clinical Genomics Market Companies:

• Illumina, Inc.

• Quest Diagnostics Incorporated

• PerkinElmer, Inc.

• Eurofins Scientific SE

• Rosetta Genomics Ltd.

• NeoGenomics Inc.

• Invitae Corporation

• Foundation Medicine, Inc.

• Genomic Health, Inc.

• Natera, Inc.

• Myriad Genetics, Inc.

• Clinical Genomics Pty Ltd.

• OPKO Health, Inc.

• 23andMe, Inc.

• Centogene AG

• Gene by Gene, Ltd.

• Iverson Genetic Diagnostics, Inc.

• GenomeDx Biosciences, Inc.

• PathGroup

• Veritas Genetics

• Personalis, Inc.

• MedGenome

• Strand Life Sciences Pvt. Ltd.

• Retrogen, Inc.

• Beijing Genomics Institute (BGI)

What is Going Around the Globe?

• In April 2025, Fortis Healthcare, a
healthcare company, launched the Genomic Medicine Institute in India.

• In April 2025, Natera, Inc., a leading
player in cell-free DNA and genetic testing, announced that its ultra-sensitive
Signatera Genome assay is widely available to physicians in the United States.

• In April 2025, Exact Sciences, a major
provider of cancer screening and diagnostic tests, launched Oncodetect, an
innovative test designed to detect molecular residual disease (MRD) across multiple
solid tumors.

• In February 2025, GeneDx, a genetic
testing company, launched ultrarapid whole genome sequencing for critically ill
infants.

• In February 2025, Strand Life Sciences
unveiled a portal for rare disease diagnosis, with affordable genetic testing.

• In June 2024, Helix, a global player in
genomic companies, launched a novel clinico-genomic dataset for cardiovascular,
metabolic, immunology, and inflammation disorders.

Clinical Genomics Market Segmentation

By Test Type

• Diagnostic Testing

• Genetic Testing

• Newborn Screening

• Preimplantation Testing

• Prenatal Testing

• Carrier Testing

• Other Tests

By Method

• Molecular Tests

• Chromosomal Tests

• Biochemical Tests

By End User

• Hospitals & Clinics

• Government Laboratories & Research
Centres

• Academics and Research Institutes

• Other End Users

By Region

• North America

• U.S.

• Canada

• Asia Pacific

• China

• Japan

• India

• South Korea

• Thailand

• Europe

• Germany

• UK

• France

• Italy

• Spain

• Sweden

• Denmark

• Norway

• Latin America

• Brazil

• Mexico

• Argentina

• Middle East and Africa (MEA)

• South Africa

• UAE

• Saudi Arabia

• Kuwait

Unlock the complete Clinical Genomics
Market report with in-depth analysis, forecasts, and competitive landscape: https://www.towardshealthcare.com/price/5754

You can place an order or ask any
questions, please feel free to contact us at sales@towardshealthcare.com

Gain access to the
latest insights and statistics in the healthcare industry by subscribing to our
Annual Membership. Stay updated on healthcare industry segmentation with
detailed reports, market trends, and expert analysis tailored to your needs.
Stay ahead of the curve with valuable resources and strategic recommendations.
Join today to unlock a wealth of knowledge and opportunities in the dynamic
world of healthcare: Get a Subscription

About Us

Towards
Healthcare is a leading global provider of
technological solutions, clinical research services, and advanced analytics,
with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we
build strategic partnerships that generate actionable insights and
transformative breakthroughs. As a global strategy consulting firm, we empower
life science leaders to gain a competitive edge, drive research excellence, and
accelerate sustainable growth.

Our Trusted Data Partners